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Protein crystallization screens
developed at the MRC Laboratory of
Molecular Biology
Fabrice Gorrec
MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0QH, UK
In order to solve increasingly challenging protein structures with crystallography, crystallization
reagents and screen formulations are regularly investigated. Here, we briefly describe 96-condition
screens developed at the MRC Laboratory of Molecular Biology: the LMB sparse matrix screen, Pi
incomplete factorial screens, the MORPHEUS grid screens and the ANGSTROM optimization screen. In
this short review, we also discuss the difficulties and advantages associated with the development of
protein crystallization screens.Introduction
X-ray crystallography is extensively applied to solve the structures
of biological macromolecules, notably proteins, their complexes
and assemblies. Recent developments in new X-ray sources and
beamlines have enabled different approaches to data collection
[1]. In addition, other techniques that can be used to solve
structures utilizing crystals are also being developed, for example
electron microscopy [2]. The resulting structures are essential to
our understanding of biological mechanisms at the atomic level
and assist rational drug design [3]. Nevertheless, protein crystalli-
zation experiments usually generate low yields of crystals with
sufficient quality to solve structures. An underlying reason for the
low yield of such crystals is the large number of combinations of
variables associated with successful protein crystallization [4]. In
addition to problems relating to the stability, shapes and surfaces
of the proteins, one has to consider experimental parameters such
as pH, temperature, physicochemical properties of the conditions,
among others. Further problems arise subsequently with the cryo-
cooling of crystals (required to reduce radiation damage during
data collection) and in data processing (since crystals are often not
sufficiently well-ordered).
Typically, crystallization involves a solution that includes three
types of reagents: a precipitant, a buffer-controlling pH and an
additive. A condition can be seen as a combination that alters the
multitude of variables associated with crystallization experiments.
There are now hundreds of well-known crystallization reagentsE-mail address: fgorrec@mrc-lmb.cam.ac.uk.
1359-6446/ 2016 The Author. Published by Elsevier Ltd. This is an open access article under the CC BY lic
http://dx.doi.org/10.1016/j.drudis.2016.03.008 and, hence, a systematic permutation of these reagents (as in
factorial or grid screens), at various concentrations, would in-
clude millions of unique combinations. However, the implemen-
tation of such a comprehensive screening program is prevented
by restricted sample quantity and the time associated with the
crystallization setup. Two main formulation approaches of ini-
tial screens have been implemented to reduce the number of
trials: incomplete factorial and sparse matrix. For the incomplete
factorial approach, conditions are formulated de novo in accor-
dance with the two principles of randomization and balance, as
suggested originally by Carter and Carter for all the main pa-
rameters related to the crystallization of tryptophan tRNA syn-
thetase [5]. The first widely used sparse matrix screen was
developed by Jancarik and Kim and involved a selection of 50
conditions that were found to have been successful with homo-
geneous samples of various kinds of proteins [6]. Over the past
decade, another approach has also been employed that consists
of integrating mixes of additives into the formulation of an
initial screen (the ‘silver bullets’ approach) [7]. After initial hits
have been obtained, in most cases one has to attempt to repro-
duce the crystals and optimize their diffraction. To do this, the
physicochemical properties of the sample, the initial conditions
employed and the cryo-cooling of crystals could be fine-tuned
with an additive screen [8].
The robotic nanoliter protein crystallization facility at the Med-
ical Research Council Laboratory of Molecular Biology (MRC LMB,
Cambridge, UK) supports more than 70 users [9]. A main feature of
this facility is the availability of 96-condition crystallization platesense (http://creativecommons.org/licenses/by/4.0/).
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FIGURE 1
(a) Pie chart showing the crystallization propensities of the main groups of
precipitants. The precipitants are found in 96 typical conditions (i.e.
conditions with a single precipitant) that were optimized at the MRC
Laboratory of Molecular Biology (LMB). Cryo-protectants (essentially glycerol)
were excluded from the analysis. Large polyethylene glycols (PEGs) are highly
successful. (b) Occurrences of pH value clusters. A wide range of pH values
needs to be investigated to crystallize different types of samples (pH 3.0–9.5)
with main occurrences of pH value clusters in the range 5.0–7.9. Note that five
out of 96 conditions were not buffered (Table S1, see supplementary material
online).
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experiments. The entire set of our pre-filled plates can be used to
form a large initial screen against a novel sample (20 plates since
2015, i.e. 1920 conditions), or just a few plates can be selected to
match specific requirements [10]. This context is ideal to investi-
gate crystallization reagents and screen formulations. Here, we
briefly describe 96-condition screens developed in our facility: (i)
the LMB sparse matrix [11]; (ii) Pi incomplete factorial screens [12];
(iii) the MORPHEUS grid screens integrating cryo-protected con-
ditions made up of multicomponent mixes [13,14]; and (iv) the
ANGSTROM optimization screen that is exclusively composed of
polyols. In this short review, we also discuss the difficulties and
advantages associated with the development of crystallization
screens.
LMB sparse matrix
Because of the unpredictable nature of protein crystallization, the
development of screens has often been driven by empirical results.
Since Jancarik and Kim’s screen, the dramatic increase in avail-
ability of crystallization data has stimulated the optimization of
sparse matrices biased toward DNA and RNA [15], transmembrane
proteins [16] and other considerations such as cost-effectiveness
[17]. Unavoidably, formulations of sparse matrices are also biased
toward the subset of initial conditions and the approach to crys-
tallization employed.
We studied the published conditions for crystal growth that
resulted in protein structures at the LMB between 2002 and 2009
[11]. In total, more than four million individual crystallization
experiments (2800 samples) were set up following standard
procedures with the vapor-diffusion technique and an initial
screen then composed of 15 pre-filled plates (i.e. 1440 conditions).
The average molecular weight of the crystallized proteins was
37 kDa, including large complexes of 100–200 kDa. Published
results with transmembrane proteins and samples containing long
nucleic acids (RNA or DNA) were excluded in this study because
they have very different physicochemical properties and hence
generally require different approaches.
Although the original purpose of our study was a statistical
analysis, a different application later emerged with the selection
of 96 non-redundant conditions that formulated a sparse
matrix for soluble proteins and their complexes with relatively
high molecular weights. Table S1 (see supplementary material
online) shows the formulation for the LMB sparse matrix screen
and all the other screens presented later (the format is database-
friendly).
Polyethylene glycols (PEGs) were found to be the most successful
precipitants (Fig. 1a), especially those with high molecular weight
(MW 1000 Da; 46% of published conditions), followed by com-
mon salts (ammonium sulfate or phosphate, sodium citrate, others)
and small volatiles (ethanol, 2-methyl-2,4-pentanediol, others).
This trend has been observed elsewhere [18], although it might
not apply to specific subsets of targets such as transmembrane
proteins [19]. The optimum pH value clusters were in the range
5.0–7.9 (72% of published conditions, Fig. 1b), whereas the pH used
to produce the samples is typically within the range 6.0–8.0. To
some extent, this corresponds to an analysis produced elsewhere
that emphasizes a well known correlation between crystallization
pH and the isoelectric point of the protein [20].820 www.drugdiscoverytoday.comPi incomplete factorial screens
In 2011, we published an incomplete factorial formulation method
called Pi sampling that is specifically applied to the standard
96-condition plate layout (i.e. columns 1–12 and rows A–H) [12].
Pi sampling is intended to help laboratories on a day-to-day basis to
formulate crystallization screens based on the properties of their
macromolecules and the techniques employed for crystallization. Pi
sampling uses modular arithmetic to generate maximally diverse
combinations of three reagents. In Fig. 2a, the stock solutions are
represented with playing cards and an example of a generated
combination is shown. Each reagent comes from one of the three
groups of 12 chosen stock solutions. Reagents are first grouped by
Drug Discovery Today  Volume 21, Number 5 May 2016 REVIEWS
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FIGURE 2
(a) Pi sampling represented with playing cards. Three sets of 12 cards (Kings excluded) represent the stock solutions grouped by class and sorted according to a
main property. Unlike most card games, the aim is to generate maximally diverse sets of cards. The triplet on the right corresponds to the condition that will be
found in well B10 according to the standard 96-condition plate layout. (b) Structure of the human adenosine A2A receptor (A2AR-GL31) bound to its endogenous
ligand adenosine. Diffraction-quality crystals of this thermostabilized G-protein-coupled receptor (GPCR) bound to different ligands were initially obtained with
screens formulated following the Pi sampling strategy, notably the Pi-PEG screen [22]. Work of Guillaume Lebon (Institut de Ge´nomique Fonctionelle, Montpellier,
France).
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pH, hygroscopy, other). Diversity between the corresponding con-
ditions is accentuated by varying the concentrations of reagents.
Ninety-six combinations are then generated with a freely available
web-based applet (http://pisampler.mrc-lmb.cam.ac.uk). The ap-
plet also generates the necessary information to prepare the corre-
sponding Pi screen by hand or with an automated system. It should
be noted that a program developed elsewhere can generate incom-
plete factorial screens with any chosen number of conditions [21].A positive impact of Pi sampling on the crystallization of a
G-protein-coupled receptor (GPCR) that had been difficult to
crystallize previously (the adenosine A2A receptor, construct
A2AR-GL31; Fig. 2b) was observed when we formulated Pi screens
such as Pi-PEG (Table S1, see supplementary material online) [22].
For the Pi-PEG, we took into consideration general observations
made in previous works with GPCRs, which indicated that the
use of screens formulated with PEGs and buffers gave a greater
yield of crystals than all commercially available screens (at least forwww.drugdiscoverytoday.com 821
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FIGURE 3
(a) MORPHEUS schematic screen layout. The layout shows a 3D grid screen with four precipitant mixes, eight additive mixes and three buffer systems
(4  8  3 = 96 conditions) found in the original MORPHEUS screen. All three stock solutions, the ligand mixes, the precipitant mixes and the buffers are combined
using a fixed volume ratio of 0.5 stock precipitants + 0.1 stock additives + 0.1 buffer-system + 0.3 water. The same approach to formulation was employed to
formulate MORHEUS II with different reagents. (b) Structure showing a cross-linked human protein tyrosine phosphatase receptor type J (PTPNJ; PDB ID: 2CFV).
The protein crystallized only as a trimer that is not observed naturally. The trimer is formed with interactions between divalent metal ions (blue spheres) and alpha-
helix structures (His-tags, blue ribbons). Unpublished results obtained during the early stage of the MORPHEUS screen development [13]. With the permission of
Alastair J. Barr (University of Westminster, London, UK).
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FIGURE 4
(a) Glycol derivatives. From top to bottom: 1,2,3-propanetriol (glycerol), 1,2,4-
butanetriol, 1,2,6-hexanetriol, 1,5-pentanediol and 1,1,1-
tris(hydroxymethyl)propane. In addition to being well-suited as crystallization
reagents, these five polyols are cryo-protectants when used at concentrations
as low as 20–25% (w/v). (b) Light photographs of crystals of endosomal
sorting complex required for transport (ESCRT)-I. Ten percent of the
ANGSTROM screen was added to the reservoirs of a crystallization plate pre-
filled with 96 repeats of the initial condition. Several hits were observed
including the one shown here with glucose as additive (final conc. 3%, w/v).
Unpublished results obtained during the early stage of the ANGSTROM
screen development. Work of Nicolas Soler (LMB).
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employed Pi sampling with success, notably during structural
studies of proteins from Gram-positive pathogens [23,24].
MORPHEUS grid screens
The formulation of a MORPHEUS screen follows a 3D grid ap-
proach, where eight mixes of additives are combined with four
precipitant mixes and three buffer systems. Fig. 3a shows the
schematic screen layout formulation for the original MORPHEUS
screen published in 2009 [13]. The use of mixes enables a more
extensive screening of components with a positive contribution to
crystallization [7]. Also, by selecting additives on their high occur-
rence in the Protein Data Bank as ligands (http://www.rcsb.org),
the chances of incorporating one that stabilizes or cross-links the
protein (Fig. 3b), or promotes crystallization in some other way,
should be increased. Finally, more than one type of additive might
be required for crystal growth, because many structures in the PDB
exhibit proteins bound with multiple additives.
In 2015, a follow-up screen called MORPHEUS II was published
[14]. MORPHEUS II integrates reagents not seen in other initial
screens commercially available. Notably, heavy atoms were used
(e.g. rare and alkali earth metals). Many heavy atoms are not very
soluble and will usually destabilize a protein. Nevertheless, heavy
atoms can opportunistically enable a crystal structure to be solved
when they become part of the crystals initially produced without
them through isomorphous replacement or even Single or Multi-
wavelength Anomalous Diffraction (SAD or MAD) method [25].
In addition to additive mixes, the MORPHEUS screens integrate
mixes of precipitants and buffer systems. Precipitants can be
mixed to have a synergistic effect and to provide cryo-protection
[26]. An advantage of buffer systems is that no concentrated acid or
base is required to alter the pH and hence the formulation becomes
fully amenable to automation. Initially, the original MORPHEUS
screen [13] generated diffraction-quality crystals for projects such
as phosphoinositide 3-kinase [27] and ubiquitin [28] and many
others at the LMB. Since then, the screen has had a clear impact in
other laboratories notably during investigations of proteins re-
quired for the outer kinetocore assembly [29] and the function of
an RNA-silencing complex [30]. Although the MORPHEUS screens
were initially intended for soluble proteins, they can also be useful
for transmembrane proteins [31], essentially because of their PEG-
based precipitants and low salt concentrations (a similar observa-
tion was made earlier about the Pi-PEG screen).
ANGSTROM optimization screen
To bypass the formation of ice crystals during flash-cooling with
liquid nitrogen or cold nitrogen gas, crystals can be pre-equilibrated
by soaking in a solution containing a cryo-protectant, in many cases
glycerol. Because the crystal structure of a protein is typically held
together by a restricted number of weak intermolecular interactions,
it can easily be damaged or lost because of different cooling rates
and expansion coefficients between the crystal and the surrounding
liquid [32]. With a multitude of possible interactions with water
and proteins via different spatial arrangements of hydroxyl
groups, polyols are ideal components to alter parameters of protein
crystallization and flash cooling of crystals. For example, polyols
have a capacity for water adsorption [33] and hence will alter
crystallization mechanisms and the kinetics of equilibration duringvapor-diffusion experiments. They can also enhance the stability of
proteins [34]. In these respects polyols lend themselves as crystalli-
zation additives.
After testing over 100 commercially available polyols, we found
about a third act as cryo-protectants, although many cryo-protect-
ing polyols were not as potent as glycerol (i.e. cryo-protectant
concentrations of 20–25%, w/v). The ANGSTROM screen was later
formulated with 31 cryoprotecting polyols at different concentra-
tions (Table S1, see supplementary material online) – essentially
derivatives of glycols (Fig. 4a), carbohydrates and PEGs. Fig. 4b
shows an example of a successful optimization experiment with awww.drugdiscoverytoday.com 823
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(ESCRT)-I.
Discussion
An underlying problem when developing a new screen is the very
large number of variables that makes comparison and validation
difficult or even impossible to achieve. Ultimately, there are never
enough samples or conditions when trying to investigate the causal
relationships that can govern crystallization of proteins. I would
argue that MORPHEUS and Pi sampling are innovative tools because
they enable the formulation of unique screens that are highly
efficient. However, it is important to acknowledge earlier work that
was a source of inspiration while designing these new tools, notably
the developments of Alexander McPherson and Bob Cudney
[7,8,35–37]. Further developments to integrate more heavy atoms
[25] and cryo-protectants [26] into crystallization protocols will be
especially useful. For example, chelates used to solubilize heavy
atoms could further facilitate novel structure solution [38]. Other
formulations to find solutions for transmembrane protein crystalli-
zation [39] and electron cryomicroscopy of two-dimensional crys-
tals [40] are being developed. Ideally, a new chemistry that opens the
way for innovative approaches needs to be introduced [41–44].
Producing protein variants is of course a major strategy to solve a
structure nowadays, notably with very advanced recombinant DNA
technologies [45], surface engineering [46] and limited proteolysis
[47]. Furthermore, the often limited amounts of sample and
cost-effectiveness should not be ignored. In this context, the
optimization of a reduced set of conditions is important [48]. We
however regularly observe the benefits of employing a wide range of
screens with proteins that were reluctant to crystallize (or formed
crystals that could not be exploited). Subsequently, I would argue
that progress in macromolecular crystallography depends on further
miniaturization of crystallization experiments to reduce costs and
enable the use of very large screens as another main strategy [49–51].824 www.drugdiscoverytoday.comConcluding remarks
Theoretical and pragmatic aspects were taken into account to
develop innovative protein crystallization screens. Because the
search space associated with diffraction-quality protein crystals
is almost infinite, the process investigated was considered as
stochastic. We hence formulated screens de novo with reagents
highly represented in crystal structures (although the LMB sparse
matrix was more safely formulated with a selection of pre-existing
conditions known to be successful).
Formulations were tested for protein stabilization, crystalliza-
tion and crystal screening with protein crystallization standards
(that crystallize readily) and challenging samples available at the
time at the LMB. We regularly obtained exclusive and useful hits in
the new screens, that means the corresponding developments had
a very positive impact on our structure-determination process. To
increase our yield of diffraction-quality crystals further, a footprint
approach to formulation [52] with innovative features is being
developed (the ‘‘Delta screen’’).
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